Joao C.R. Freitas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joao C.R. Freitas has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Abigail J. Porzucek
Yale School of Public Health 4 Department of Epidemiology of Microbial Diseases New Haven, CT
1 shared publication Ana B. de Oliveira
Faculdade de Medicina de São José do Rio Preto 6 Laboratório de Pesquisas em Virologia, Departamento de Doenças dermatológicas, Infecciosas e Parasitárias São José do Rio Preto
1 shared publication- Carolina Lucas
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
1 shared publication - Daniela Weiskopf
Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, USA
1 shared publication - David R. Martinez
Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA
1 shared publication - Fahima Akther
Yale University School of Medicine 1 Department of Immunobiology New Haven, CT
1 shared publication
Latest Publications
- 2 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.
- 2 September 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (10)
Serotype skewing and immune imprinting shape response to the tetravalent dengue virus Qdenga vaccine
Dengue causes over 390 million annual infections globally. Qdenga (TAK-003), the only widely available dengue vaccine, has an incompletely defined immunological profile. We performed longitudinal immunological profiling of 110 adults from a dengue-endemic region, including older adults (≥65 years), to assess the effects of immune imprinting and vaccine design on humoral and cellular immunity. Qdenga elicited B and T cell activation across groups but generated serostatus-dependent, serotype-skewed antibody responses. Only 8% of DENV-naïve individuals developed tetravalent neutralizing responses, whereas one-third responded to a single serotype, predominantly DENV-2, the vaccine backbone. DENV-exposed individuals mounted broader responses shaped by preexisting immunity, yet DENV-4 neutralization remained consistently poor. Neutralizing antibody titers plateaued after the first dose, with no increase following the second. These findings clarify why balanced tetravalent immunity is rarely achieved with Qdenga and demonstrate that both immune imprinting and vaccine backbone limit the breadth and magnitude of the responses. This has important implications for deployment, long-term protection in naive populations, and DENV-4–targeted boosters.